Dr Thierry Virolle is Director of Research at Institut National de la Santé et de la Recherche Médicale. He is leading the Team “Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity” at the Institute of Biology Valrose (iBV) at Nice. Dr Virolle obtained his PhD in 2000 and his HDR (habilitation to direct research) in 2004 at the university of Nice Sophia-Antipolis. He completed is post-doctoral studies at Pr Eileen Adamson’s laboratory (The Burnham Institute, San Diego, CA, USA), where he characterizes EGR1 function in UV stress response and epithelial cancer (Nature Cell Biology 2002 ; JBC 2003). Since then, as Principal Investigator, he has published several papers describing molecular mechanisms and gene regulatory networks involved in UV-induced DNA damages (Embo J 2005, Cell Death Differ 2008; Cell Death Differ 2009). Since 2009, Dr Virolle’s team has been focusing on the study of cancer stem cell plasticity in glioblastoma. They have described original transcription factors and miRNA signatures that control glioma stem cell fate and tumorigenicity (Cell Death Differ 2012, Stem Cells 2013, Neuro Oncology 2013, Biomaterials 2013, JBC 2016, Cell Death and dis 2017, Oncogene 2018, Cancer Research 2020). Based on these results, he developed a novel therapeutic approach for glioblastoma treatment, the “differentiating strategy” (patented), leading to the differentiation of glioma stem cell and the loss of their tumorigenic property.
Dr Thierry Virolle is Director of Research at Institut National de la Santé et de la Recherche Médicale. He is leading the Team “Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity” at the Institute of Biology Valrose (iBV) at Nice. Dr Virolle obtained his PhD in 2000 and his HDR (habilitation to direct research) in 2004 at the university of Nice Sophia-Antipolis. He completed is post-doctoral studies at Pr Eileen Adamson’s laboratory (The Burnham Institute, San Diego, CA, USA), where he characterizes EGR1 function in UV stress response and epithelial cancer (Nature Cell Biology 2002 ; JBC 2003). Since then, as Principal Investigator, he has published several papers describing molecular mechanisms and gene regulatory networks involved in UV-induced DNA damages (Embo J 2005, Cell Death Differ 2008; Cell Death Differ 2009). Since 2009, Dr Virolle’s team has been focusing on the study of cancer stem cell plasticity in glioblastoma. They have described original transcription factors and miRNA signatures that control glioma stem cell fate and tumorigenicity (Cell Death Differ 2012, Stem Cells 2013, Neuro Oncology 2013, Biomaterials 2013, JBC 2016, Cell Death and dis 2017, Oncogene 2018, Cancer Research 2020). Based on these results, he developed a novel therapeutic approach for glioblastoma treatment, the “differentiating strategy” (patented), leading to the differentiation of glioma stem cell and the loss of their tumorigenic property.